Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Horizon Therapeutics to Expand Pipeline, R&D with $3B Viela Bio Acquisition
Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyer s pipeline and R&D. [Viela Bio]
February 1, 2021
Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyer s pipeline and R&D. [Viela Bio]
Share
Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said today less than three weeks after Horizon president and CEO Tim Walbert told
GEN that his company intended to expand its pipeline through mergers and acquisitions and beef up its R&D this year.
Posted on 194
AVANGRID, Inc. (NYSE: AGR), a leading clean energy company, confirmed today that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) has expired in relation to the proposed merger combination with PNM Resources (NYSE: PNM).
The company continues to pursue state and Federal regulatory approvals for the merger, including approvals from the Federal Energy Regulatory Commission, the Federal Communications Commission, the Federal Nuclear Regulatory Commission, the Committee on Foreign Investment in the US, as well as the New Mexico Public Regulation Commission and the Public Utility Commission of Texas. The agreement between AVANGRID and PNM Resources is also subject to approval by PNM Resources’ shareholders.